Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9995950 | 0.79 | CA2 (0.33) | HCRTR2HCRTR1CXCR1CXCR2CA2 | |
| SCHEMBL9995998 | 0.79 | CA2 (0.33) | HCRTR2HCRTR1CXCR1CXCR2CA2 | |
| SCHEMBL4264474 | 0.79 | CA2 (0.33) | HCRTR2HCRTR1CXCR1CXCR2CA2 | |
| SCHEMBL4062962 | 0.79 | CA2 (0.33) | HCRTR2HCRTR1CXCR1CXCR2CA2 | |
| SCHEMBL13528024 | 0.79 | HCRTR2 (0.40) | HCRTR2HCRTR1CA2 | |
| SCHEMBL25387433 | 0.77 | HCRTR1 (0.35) | HCRTR2HCRTR1CA2 | |
| SCHEMBL346996 | 0.77 | HCRTR1 (0.35) | HCRTR2HCRTR1CA2 | |
| SCHEMBL18682065 | 0.77 | HCRTR1 (0.35) | HCRTR2HCRTR1CA2 | |
| SCHEMBL5338406 | 0.77 | HCRTR2 (0.33) | HCRTR2HCRTR1CA2 | |
| SCHEMBL8169843 | 0.77 | HCRTR1 (0.35) | HCRTR2HCRTR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | HCRTR2 2344/4885HCRTR1 1886/4885CXCR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.